San Bruno, CA-based Numerate has wrapped a $5.5 million Series B round to help finance its drug engineering work. Foundation Capital led the round and was joined by Lanza techVentures, both existing investors.

"This increased investment demonstrates our confidence in the ability of Numerate's computationally-based drug design process to deliver high-potential clinical candidates at a fraction of the cost and time required by traditional processes," said Adam Grosser, a general partner with Foundation Capital. "We believe there is a large opportunity for this innovative technology to address industry-wide needs for greater efficiency and less risk in drug discovery."

"This investment will help support our business model of partnering with biotechnology and pharmaceutical companies while building on our drug design platform that provides compounds with the best chance of succeeding in the lab, clinic and marketplace," said Numerate CEO Guido Lanza.

- check out Numerate's release for more

Related Article:
Numerate completes $4M financing